Spinal Cord Lesions in Patients with Neuromyelitis Optica: A Retrospective Long-Term MRI Follow-Up Study
Eur Radiol 19:2535-2543, Krampla, W.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Five Cases of Malignant Melanoma During Fingolimod Treatment in Dutch Patients with MS
Neurol 89:970-972, Killestein, J.,et al, 2017
A Patient with a History of Encephalomyelitis and Recurrent Optic Neuritis
Neurol 89:e231-e234, Gutman, J.M.,et al, 2017
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
The Useless Hand of Oppenheim
Pract Neurol 17:464-468, Wiblin, L. & Guadagno, J., 2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
Characteristics in Limbic Encephalitis with Anti-Adenylate Kinase 5 Autoantibodies
Neurol 88:514-524,508, Do, L. & Chanson, E., 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
A Man with Rapidly Ascending Paralysis
Neurol 89:e25-e31, Rosenberg, J.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016
Discriminating Long Myelitis of Neuromyelitis Optica from Sarcoidosis
Ann Neurol 79:437-447, Flanagan, E.P.,et al, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Rebound Syndrome in Patients with Multiple Sclerosis after Cessation of Fingolimod Treatment
JAMA Neurol 73:790-794, Hatcher, S.E.,et al, 2016
Incidence of Radiologically Isolated Syndrome: A Population-Based Study
AJNR 37:1017-1022, Forslin, Y.,et al, 2016
Neuromyelitis Optica Spectrum Disorders
UpToDate, May, Glisson,C.C., 2016
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Persistent Hyperthermia in a Patient with Aquaporin-4-Antibody-Positive Neuromyelitis Optica Spectrum Disorder
J Clin Neurol 12:515-516, Hsu,C-L.,et al, 2016
Marburgs Variant of Multiple Sclerosis with Extensive Brain Lesions
Int J Neurol Neurother doi:10.23937/2378-3001/2/1/1027, Ludwig, A.,et al, 2015
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Reversible Cerebral Vasoconstriction Syndrome, Part 1: Epidemiology, Pathogenesis, and Clinical Course
AJNR 36:1392-1399, Miller, T.R.,et al, 2015
Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP):A Randomised, Controlled, Double-Blind,Non-Inferiority Trial
Lancet 386:974-981, LePage,E.,et al, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Bionic Reconstruction to Restore Hand Function After Brachial Plexus Injury: A Case Series of Three Patients
Lancet 385:2183-2189, Aszmann, O.C.,et al, 2015
International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders
Neurol 85:177-189, Wingerchuk, D.M.,et al, 2015
Relapse in Multiple Sclerosis
BMJ 350:h1765, Galea, I.,et al, 2015
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015
Characteristics of Lumbar Disc Herniation with Exacerbation of Presentation Due to Spinal Manipulative Therapy
Medicine 94:e661, Huang, S.L.,et al, 2015
Investigation of Leptomeningeal Enhancement in MS
Neurol 84:770-775, Eisele, P.,et al, 2015
Short Myelitis Lesions in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders
JAMA Neurol 72:81-87, Flanagan, E.P.,et al, 2015
MRI Characteristics of Neuromyelitis Optica Spectrum Disorder
Neurol 84:1165-1173, Jin Kim, H.,et al, 2015
Superficial Abdominal Reflex
NEJM 370:e29, Baden, L.R., 2014
Enterovirus Vaccines for an Emerging Cause of Brain-Stem Encephalitis
NEJM 370:792-794, McMinn, P.C., 2014
Relapsing-Remitting Tumefactive Demyelination
JAMA Neurol 71:366-367, Brandao, E.,et al, 2014
Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Effects of Bacille Calmette-Guerin after the first Demyelinating event in the CNS
Neurol 82:41-48, Ristori, G.,et al, 2014
Progressive Cerebellar Ataxia and New-Onset Diabetes
Lancet 383:186, Kong, M.,et al, 2014